Advanced Biliary Tract Cancer Clinical Trial
Official title:
Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers: a Single-arm, Non-randomized, Single-center Clinical Trial and Biomarker Study
The investigators design a phase II clinical study to explore the efficacy and safety of toripalimab plus lenvatinib as a second-line treatment in patients with advanced biliary tract cancers and to analyze potential biomarkers of therapeutic response.
This phase II trial is a single-arm, non-randomized and single-center clinical study. It is estimated that 44 patients who met the study criteria will be enrolled in 2 years and treated with toripalimab plus lenvatinib in PUMCH. The investigators will follow up and collect subjects' data each month to evaluate the efficacy and safety of treatment, including overall survival and time to progression, until disease progression or death. Interim analysis and final analysis will be conducted when collecting data from 20 and 44 subjects, respectively in this trial. Histopathology and multi-omics data analysis will be used to explore potential biomarkers of treatment response. Study Type: Interventional. Masking: Open Label. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05009953 -
Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer
|
Phase 2 | |
| Recruiting |
NCT05820906 -
Cadonilimab Plus Regorafenib and Gem-Cis Chemotherapy in Advanced Biliary Tract Cancer
|
Phase 2 | |
| Completed |
NCT03358849 -
Phase 1 Clinical Trial to Evaluate the Safety of Allogeneic NK Cell ("SMT-NK") Cell Therapy in Advanced Biliary Tract Cancer
|
Phase 1 | |
| Recruiting |
NCT05410197 -
Envofolimab and Lenvatinib Combined With Gemcitabine Plus Cisplatin for Advanced BTC as First-Line Treatment(ENLIGHTEN)
|
Phase 2 | |
| Active, not recruiting |
NCT04727996 -
Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract Cancer
|
Phase 2 | |
| Recruiting |
NCT05823987 -
Oncolytic Virotherapy Combined With Tislelizumab Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer (OPTIONS-05)
|
Phase 2 | |
| Not yet recruiting |
NCT04733521 -
A Phase 1/2 Study of SC-43 in Combination With Cisplatin
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04027764 -
Toripalimab Combined With S1 and Albumin Paclitaxel in Patients With Advanced Biliary Tract Cancer
|
Phase 2 | |
| Recruiting |
NCT05781074 -
Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Biliary Tract Cancer （CASTLE-08）
|
Phase 2 | |
| Recruiting |
NCT04781192 -
The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05653180 -
IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04005339 -
NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer
|
Phase 2 | |
| Completed |
NCT04217954 -
HAIC With Oxaliplatin, 5-FU and Bevacizumab Plus Intravenous Toripalimab for Advanced BTC
|
Phase 2 | |
| Recruiting |
NCT05170438 -
Lenvatinib Plus Paclitaxel for Patients With Advanced Biliary Tract Cancer Who Failed to Gemcitabine-based Treatment
|
Phase 2 | |
| Active, not recruiting |
NCT04172402 -
NGS as the First-line Treatment in Advanced Biliary Tract Cancer
|
Phase 2 | |
| Withdrawn |
NCT02597465 -
A Randomized, Open-Label, Comparative, Parallel-Group, Multicenter Study of SPARC1507
|
Phase 3 | |
| Active, not recruiting |
NCT04969887 -
Combination Immunotherapy in Rare Cancers Under InvesTigation
|
Phase 2 | |
| Recruiting |
NCT05812430 -
Anlotinib Plus TQB2450 Combined With Nab-paclitaxel and Cisplatin as First-line Treatment for Advanced Biliary Tract Cancer
|
Phase 2 |